{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:34:25Z","timestamp":1773034465607,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included &lt;50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio)therapy and autoSCT. From January 2001 to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not specified (<jats:italic>n=<\/jats:italic>42) and angioimmunoblastic T-cell lymphoma (<jats:italic>n=<\/jats:italic>37). Seventy-five (68%) of the 111 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%. The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively. The results of this study confirm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL and therefore should be part of first-line therapy whenever possible.<\/jats:p>","DOI":"10.1038\/bcj.2016.63","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T16:14:36Z","timestamp":1469808876000},"page":"e452-e452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation"],"prefix":"10.1038","volume":"6","author":[{"given":"M","family":"Wilhelm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Smetak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Geissinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruediger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Schaefer-Eckart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-9838","authenticated-orcid":false,"given":"J","family":"Birkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"BFbcj201663_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcome. J Clin Oncol 2008; 26: 4124\u20134130.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR2","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/annonc\/mdu152","volume":"25","author":"P Corradini","year":"2014","unstructured":"Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S et al. SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol 2014; 25: 2339\u20132350.","journal-title":"Ann Oncol"},{"key":"BFbcj201663_CR3","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T . Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014; 124: 1570\u20131577.","journal-title":"Blood"},{"key":"BFbcj201663_CR4","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-Cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496\u20135504.","journal-title":"Blood"},{"key":"BFbcj201663_CR5","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467\u20131475.","journal-title":"Ann Oncol"},{"key":"BFbcj201663_CR6","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402\u20133408.","journal-title":"Blood"},{"key":"BFbcj201663_CR7","first-page":"171","volume":"82","author":"F Zaja","year":"1997","unstructured":"Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: Clinical characteristics and outcome. Haematologica 1997; 82: 171\u2013177.","journal-title":"Haematologica"},{"key":"BFbcj201663_CR8","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","volume":"121","author":"E Jantunen","year":"2013","unstructured":"Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013; 121: 2529\u20132532.","journal-title":"Blood"},{"key":"BFbcj201663_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.seminhematol.2013.11.002","volume":"51","author":"P Giulia","year":"2014","unstructured":"Giulia P, Corradini P . Autologous stem cell transplantation for T-cell lymphomas. Semin Hematol 2014; 51: 59\u201366.","journal-title":"Semin Hematol"},{"key":"BFbcj201663_CR10","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","volume":"20","author":"C Gisselbrecht","year":"2002","unstructured":"Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472\u20132479.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106\u2013113.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR12","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F D'Amore","year":"2012","unstructured":"D'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Upfront autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093\u20133099.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533\u20131538.","journal-title":"Leukemia"},{"key":"BFbcj201663_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958\u2013963.","journal-title":"Ann Oncol"},{"key":"BFbcj201663_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodriguez","year":"2007","unstructured":"Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32\u201338.","journal-title":"Eur J Haematol"},{"key":"BFbcj201663_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol 1999; 17: 1244\u20131253.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL . A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343\u2013346.","journal-title":"Control Clin Trials"},{"key":"BFbcj201663_CR18","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM . How I treat peripheral T-cell lymphomas. Blood 2014; 123: 2636\u20132644.","journal-title":"Blood"},{"key":"BFbcj201663_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11864-013-0232-x","volume":"14","author":"MA Lunning","year":"2013","unstructured":"Lunning MA, Horwitz SM . Treatment of peripheral T-cell lymphoma: Are we data driven or driving the data? Curr Treat Options Oncol 2013; 14: 212\u2013223.","journal-title":"Curr Treat Options Oncol"},{"key":"BFbcj201663_CR20","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/cncr.28676","volume":"120","author":"AF Herrera","year":"2014","unstructured":"Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI et al. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer 2014; 120: 1993\u20131999.","journal-title":"Cancer"},{"key":"BFbcj201663_CR21","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418\u20133425.","journal-title":"Blood"},{"key":"BFbcj201663_CR22","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920\u20132924.","journal-title":"Blood"},{"key":"BFbcj201663_CR23","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van BK, Lerademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature T-cell Non-Hodgkin Lymphoma. J Clin Oncol 2013; 31: 3100\u20133109.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.seminhematol.2013.11.010","volume":"51","author":"N Schmitz","year":"2014","unstructured":"Schmitz N, Wu HS, Glass B . Allogenic transplantation in T-cell-Lymphomas. Semin Hematol 2014; 51: 67\u201372.","journal-title":"Semin Hematol"},{"key":"BFbcj201663_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000358579","volume":"133","author":"J Wei","year":"2014","unstructured":"Wei J, Xu J, Cao Y, Zhou J, Zhang Y et al. Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis. Acta Haematol 2014; 133: 136\u2013144.","journal-title":"Acta Haematol"},{"key":"BFbcj201663_CR26","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","volume":"52","author":"J Zain","year":"2011","unstructured":"Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A et al. Allogeneic hematopoietic cell transplantation for peripheral T-cell NHL results in long-term disease control. Leuk Lymphoma 2011; 52: 1463\u20131473.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201663_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/annonc\/mdu515","volume":"26","author":"M Loirat","year":"2015","unstructured":"Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015; 26: 386\u2013392.","journal-title":"Ann Oncol"},{"key":"BFbcj201663_CR28","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation for hematopoietic cells. J Clin Oncol 2004; 22: 2172\u20132176.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR29","first-page":"abstr 033","volume":"33","author":"N Schmitz","year":"2015","unstructured":"Schmitz N, Nickelsen M, Altmann B, Ziepert M, Bouabdallah K, Gisselbrecht C et al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T cell lymphoma \u2013 Results of the interim analysis of the AATT trial. Hematol Oncol 2015; 33: abstr 033.","journal-title":"Hematol Oncol"},{"key":"BFbcj201663_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/leu.2014.280","volume":"29","author":"A Tanase","year":"2015","unstructured":"Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma working Party. Leukemia 2015; 29: 686\u2013688.","journal-title":"Leukemia"},{"key":"BFbcj201663_CR31","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","volume":"120","author":"T Ishida","year":"2012","unstructured":"Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 2012; 120: 1734\u20131741.","journal-title":"Blood"},{"key":"BFbcj201663_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","volume":"20","author":"GS Falchook","year":"2009","unstructured":"Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20: 1080\u20131085.","journal-title":"Ann Oncol"},{"key":"BFbcj201663_CR33","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190\u20132196.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR34","doi-asserted-by":"crossref","first-page":"abstr 368","DOI":"10.1182\/blood.V122.21.368.368","volume":"122","author":"S Redaelli","year":"2013","unstructured":"Redaelli S, Farina F, Stasia A, Ceccon M, Mologni L, Messa C et al. High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Blood 2013; 122: abstr 368.","journal-title":"Blood"},{"key":"BFbcj201663_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631\u2013636.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M, Hymes KB . A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 2015; 168: 811\u2013819.","journal-title":"Br J Haematol"},{"key":"BFbcj201663_CR37","doi-asserted-by":"crossref","first-page":"abstr 8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","volume":"31","author":"OA O\u00b4Connor","year":"2013","unstructured":"O\u00b4Connor OA, Masszi T, Savage KJ, Pinter-Brown LC, Foss FM, Popplewell L et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma(R\/R PTCL): results from the BELIEF trial. J Clin Oncol 2013; 31: abstr 8507.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR38","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182\u20131189.","journal-title":"J Clin Oncol"},{"key":"BFbcj201663_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014; 7: 11.","journal-title":"J Hematol Oncol"},{"key":"BFbcj201663_CR40","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-14-2020","volume":"20","author":"OA O'Connor","year":"2014","unstructured":"O'Connor OA, Bhagat G, Ganapathi K, Pedersen MB, d'Amore F, Radeski D et al. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clin Cancer Res 2014; 20: 5240\u20135254.","journal-title":"Clin Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201663","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201663.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:07:13Z","timestamp":1672823233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,29]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["BFbcj201663"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.63","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,29]]},"assertion":[{"value":"14 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MW, MS, EG, TR, BM and KSE have nothing to disclose, PR has honoraria (Pfizer, Celgene, Takeda, Roche) to disclose and travel expenses (Celgene, Roche, Mundipharma, Takeda, Nexion), NS has stock ownership to disclose (Celgene), honoraria (Roche, Takeda, Riemser, Gilead) and consulting (Roche, Gilead, Riemser, Takeda, cti), AE has honoraria, consulting and research funding (Takeda, Millennium) to disclose, JB has honoraria and travel expenses (both Mundipharma) to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}